SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kuldeep Sharma, Kalpeshkumar Giri, Vinay Dhiman, Abhishek Dixit, Mohd Zainuddin, Ramesh Mullangi, A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study, Biomedical Chromatography, 2015, 29, 5
  2. 2
    Young Ho Lee, Sang-Cheol Bae, Gwan Gyu Song, Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials, Rheumatology International, 2015,

    CrossRef

  3. 3
    F. Vincenti, H. T. Silva, S. Busque, P. J. O'Connell, G. Russ, K. Budde, A. Yoshida, M. A. Tortorici, M. Lamba, N. Lawendy, W. Wang, G. Chan, Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients, American Journal of Transplantation, 2015, 15, 6
  4. 4
    Joel M Kremer, Alan J Kivitz, Jesus A Simon-Campos, Evgeny L Nasonov, Hans-Peter Tony, Soo-Kon Lee, Bonnie Vlahos, Constance Hammond, Jack Bukowski, Huihua Li, Seth L Schulman, Susan Raber, Andrea Zuckerman, John D Isaacs, Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial, Arthritis Research & Therapy, 2015, 17, 1

    CrossRef

  5. 5
    Satoshi Suzuki, Shinji Morimoto, Maki Fujishiro, Mikiko Kawasaki, Kunihiro Hayakawa, Tomoko Miyashita, Keigo Ikeda, Keiji Miyazawa, Mitsuaki Yanagida, Kenji Takamori, Hideoki Ogawa, Iwao Sekigawa, Yoshinari Takasaki, Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis, Autoimmunity, 2015, 48, 4, 251

    CrossRef

  6. 6
    Alejandro Souto, Eva Salgado, José Ramón Maneiro, Antonio Mera, Loreto Carmona, Juan J. Gómez-Reino, Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis, Arthritis & Rheumatology, 2015, 67, 1
  7. 7
    Christina Charles-Schoeman, Roy Fleischmann, Jean Davignon, Howard Schwartz, Scott M. Turner, Carine Beysen, Mark Milad, Marc K. Hellerstein, Zhen Luo, Irina V. Kaplan, Richard Riese, Andrea Zuckerman, Iain B. McInnes, Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib, Arthritis & Rheumatology, 2015, 67, 3
  8. 8
    Suzanne J. Tintle, Alice B. Gottlieb, Psoriatic Arthritis for the Dermatologist, Dermatologic Clinics, 2015, 33, 1, 127

    CrossRef

  9. 9
    Yoshiya Tanaka, Samuel H. Zwillich, Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis, Modern Rheumatology, 2015, 1

    CrossRef

  10. 10
    Maria A Lopez-Olivo, Huifang Lu, Jean H Tayar, Review of tofacitinib in rheumatoid arthritis, Clinical Investigation, 2015, 5, 1, 23

    CrossRef

  11. 11
    Sriram Krishnaswami, Mary Boy, Vincent Chow, Gary Chan, Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers, Clinical Pharmacology in Drug Development, 2015, 4, 2
  12. 12
    Mark C. Genovese, Roy Fleischmann, Alan J. Kivitz, Maria Rell-Bakalarska, Renata Martincova, Stefano Fiore, Patricia Rohane, Hubert van Hoogstraten, Anju Garg, Chunpeng Fan, Janet van Adelsberg, Steven P. Weinstein, Neil M. H. Graham, Neil Stahl, George D. Yancopoulos, Tom W. J. Huizinga, Désirée van der Heijde, Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study, Arthritis & Rheumatology, 2015, 67, 6
  13. 13
    D. L. Boyle, K. Soma, J. Hodge, A. Kavanaugh, D. Mandel, P. Mease, R. Shurmur, A. K. Singhal, N. Wei, S. Rosengren, I. Kaplan, S. Krishnaswami, Z. Luo, J. Bradley, G. S. Firestein, The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis, Annals of the Rheumatic Diseases, 2015, 74, 6, 1311

    CrossRef

  14. 14
    John J. O'Shea, Daniella M. Schwartz, Alejandro V. Villarino, Massimo Gadina, Iain B. McInnes, Arian Laurence, The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention*, Annual Review of Medicine, 2015, 66, 1, 311

    CrossRef

  15. 15
    Vibeke Strand, Gerd R. Burmester, Cristiano A. F. Zerbini, Charles A. Mebus, Samuel H. Zwillich, David Gruben, Gene V. Wallenstein, Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial, Arthritis Care & Research, 2015, 67, 4
  16. 16
    Yoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, Hiroyuki Nakamura, Shigeyuki Toyoizumi, Samuel Zwillich, Efficacy and Safety of Tofacitinib as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis: A 12-Week, Randomized, Phase 2 Study, Modern Rheumatology, 2014, 1

    CrossRef

  17. 17
    C. Gaujoux-Viala, J. Nam, S. Ramiro, R. Landewe, M. H. Buch, J. S. Smolen, L. Gossec, Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Annals of the Rheumatic Diseases, 2014, 73, 3, 510

    CrossRef

  18. 18
    J. S. Smolen, R. Landewe, F. C. Breedveld, M. Buch, G. Burmester, M. Dougados, P. Emery, C. Gaujoux-Viala, L. Gossec, J. Nam, S. Ramiro, K. Winthrop, M. de Wit, D. Aletaha, N. Betteridge, J. W. J. Bijlsma, M. Boers, F. Buttgereit, B. Combe, M. Cutolo, N. Damjanov, J. M. W. Hazes, M. Kouloumas, T. K. Kvien, X. Mariette, K. Pavelka, P. L. C. M. van Riel, A. Rubbert-Roth, M. Scholte-Voshaar, D. L. Scott, T. Sokka-Isler, J. B. Wong, D. van der Heijde, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Annals of the Rheumatic Diseases, 2014, 73, 3, 492

    CrossRef

  19. 19
    Kevin L. Winthrop, Hisashi Yamanaka, Hernan Valdez, Eric Mortensen, Robert Chew, Sriram Krishnaswami, Thomas Kawabata, Richard Riese, Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis, Arthritis & Rheumatology, 2014, 66, 10
  20. 20
    Henk M. van Beuningen, Marloes L. de Vries-van Melle, Elly L. Vitters, Wim Schreurs, Wim B. van den Berg, Gerjo J.V.M. van Osch, Peter M. van der Kraan, Inhibition of TAK1 and/or JAK Can Rescue Impaired Chondrogenic Differentiation of Human Mesenchymal Stem Cells in Osteoarthritis-Like Conditions, Tissue Engineering Part A, 2014, 20, 15-16, 2243

    CrossRef

  21. 21
    Leeyen Hsu, April W. Armstrong, JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis, Journal of Immunology Research, 2014, 2014, 1

    CrossRef

  22. 22
    Kamran Ghoreschi, Massimo Gadina, Jakpot! New small molecules in autoimmune and inflammatory diseases, Experimental Dermatology, 2014, 23, 1
  23. You have free access to this content23
    Lindsey A. MacFarlane, Derrick J. Todd, Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis, International Journal of Rheumatic Diseases, 2014, 17, 4
  24. 24
    Mi Kyoung Kim, Heerim Shin, Seo Young Cho, Youhoon Chong, Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group, Bioorganic & Medicinal Chemistry, 2014, 22, 3, 1156

    CrossRef

  25. 25
    Stephan Blüml, Kurt Redlich, Josef S. Smolen, Mechanisms of tissue damage in arthritis, Seminars in Immunopathology, 2014, 36, 5, 531

    CrossRef

  26. 26
    Renata Baronaite Hansen, Arthur Kavanaugh, Novel Treatments with Small Molecules in Psoriatic Arthritis, Current Rheumatology Reports, 2014, 16, 9

    CrossRef

  27. 27
    Eva Salgado, José Ramón Maneiro, Nuevos tratamientos en artritis reumatoide, Medicina Clínica, 2014, 143, 10, 461

    CrossRef

  28. 28
    Sriram Krishnaswami, Vincent Chow, Mary Boy, Cunshan Wang, Gary Chan, Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease, The Journal of Clinical Pharmacology, 2014, 54, 1
  29. 29
    Florian M.P. Meier, Iain B. McInnes, Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety, Best Practice & Research Clinical Rheumatology, 2014, 28, 4, 605

    CrossRef

  30. 30
    Kirandeep Kaur, Sonesh Kalra, Sandeep Kaushal, Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis, Clinical Therapeutics, 2014, 36, 7, 1074

    CrossRef

  31. 31
    Kunihiro Yamaoka, Yoshiya Tanaka, Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib, Expert Opinion on Pharmacotherapy, 2014, 15, 1, 103

    CrossRef

  32. 32
    Charlotte Rawlings, Ernest Choy, The future of biological agents in the treatment of rheumatoid arthritis, International Journal of Clinical Rheumatology, 2014, 9, 5, 475

    CrossRef

  33. 33
    Kabita Nanda, Carol Ann Wallace, The future of treatment for juvenile idiopathic arthritis, International Journal of Clinical Rheumatology, 2014, 9, 2, 135

    CrossRef

  34. 34
    Xingming Zhang, Fuxiang Liang, Xiaoxue Yin, Xiaojuan Xiao, Peiyu Shi, Dang Wei, Liang Yao, Qi Wang, Yaolong Chen, Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis, Clinical Rheumatology, 2014, 33, 2, 165

    CrossRef

  35. 35
    Eun Bong Lee, Roy Fleischmann, Stephen Hall, Bethanie Wilkinson, John D. Bradley, David Gruben, Tamas Koncz, Sriram Krishnaswami, Gene V. Wallenstein, Chuanbo Zang, Samuel H. Zwillich, Ronald F. van Vollenhoven, Tofacitinib versus Methotrexate in Rheumatoid Arthritis, New England Journal of Medicine, 2014, 370, 25, 2377

    CrossRef

  36. 36
    Christopher Chang, Unmet needs in the treatment of autoimmunity: From aspirin to stem cells, Autoimmunity Reviews, 2014, 13, 4-5, 331

    CrossRef

  37. 37
    Florian MP Meier, Marc Frerix, Walter Hermann, Ulf Müller-Ladner, Current immunotherapy in rheumatoid arthritis, Immunotherapy, 2013, 5, 9, 955

    CrossRef

  38. 38
    B. Strober, M. Buonanno, J.D. Clark, T. Kawabata, H. Tan, R. Wolk, H. Valdez, R.G. Langley, J. Harness, A. Menter, K. Papp, Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment, British Journal of Dermatology, 2013, 169, 5
  39. 39
    Ying He, Angel YS Wong, Esther W Chan, Wallis CY Lau, Kenneth KC Man, Celine SL Chui, Alan J Worsley, Ian CK Wong, Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis, BMC Musculoskeletal Disorders, 2013, 14, 1, 298

    CrossRef

  40. 40
    Asres Berhan, Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies, BMC Musculoskeletal Disorders, 2013, 14, 1, 332

    CrossRef

  41. 41
    K. Migita, Y. Izumi, T. Torigoshi, K. Satomura, M. Izumi, Y. Nishino, Y. Jiuchi, M. Nakamura, H. Kozuru, F. Nonaka, K. Eguchi, A. Kawakami, S. Motokawa, Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds, Clinical & Experimental Immunology, 2013, 174, 3
  42. 42
    Soumya D. Chakravarty, Poulikos I. Poulikakos, Lionel B. Ivashkiv, Jane E. Salmon, George D. Kalliolias, Kinase inhibitors: A new tool for the treatment of rheumatoid arthritis, Clinical Immunology, 2013, 148, 1, 66

    CrossRef

  43. 43
    Natasha Jordan, Pamela MK Lutalo, David P D’Cruz, Novel therapeutic agents in clinical development for systemic lupus erythematosus, BMC Medicine, 2013, 11, 1, 120

    CrossRef

  44. 44
    Douglas Veale, Psoriatic arthritis: recent progress in pathophysiology and drug development, Arthritis Research & Therapy, 2013, 15, 6, 224

    CrossRef

  45. 45
    Paweł Kawalec, Alicja Mikrut, Natalia Wiśniewska, Andrzej Pilc, The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis, Clinical Rheumatology, 2013, 32, 10, 1415

    CrossRef

  46. 46
    Geom Seog Seo, The Efficacy and Safety of a Tofacitinib in the Treatment of Active Ulcerative Colitis, The Korean Journal of Gastroenterology, 2013, 61, 6, 354

    CrossRef

  47. 47
    Eva Salgado, Juan J Gómez-Reino, The JAK inhibitor tofacitinib for active rheumatoid arthritis: results from Phase III trials, International Journal of Clinical Rheumatology, 2013, 8, 3, 315

    CrossRef

  48. 48
    Chadi Rakieh, Philip G. Conaghan, Tofacitinib for Treatment of Rheumatoid Arthritis, Advances in Therapy, 2013, 30, 8, 713

    CrossRef

  49. 49
    Joon Wan Kim, In Ah Choi, Eun Young Lee, Yeong Wook Song, Eun Bong Lee, Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis, Journal of Korean Medical Science, 2013, 28, 8, 1134

    CrossRef

  50. 50
    Lesley J. Scott, Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis, Drugs, 2013, 73, 8, 857

    CrossRef